REVELATION BIOSCIENCES, INC. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
On July 10, 2026, Revelation Biosciences' Board adopted a stockholder rights plan and declared a dividend of one right per outstanding common share (record date July 21, 2026). Each right entitles holders to purchase 1/1,000th of a Series B Junior Participating Preferred Share at $20.00 upon triggering (10%+ ownership without Board approval). The plan includes flip-in rights (cheap common stock purchase at 50% discount if triggered), exchange rights, and redemption at $0.001/right pre-trigger. Rights expire in 1 year unless shareholders approve by year 3. Counterparty is Continental Stock Transfer Trust Co. as rights agent.
Why this rating
Standard anti-takeover measure for micro-cap ($3.4M). No new capital, cash outlay, or operational impact. Routine defensive governance common at public biotech firms.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.